Shannon Connelly

The 4-drug combination of rituximab, bendamustine, bortezomib, and dexamethasone was found to improve progression-free survival and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma who are ≥65 years.

Maria-Victoria Mateos, MD, PhD, discusses the updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.

Krish Patel, MD, discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

The PD-L1 immunohistochemistry 22C3 pharmDx can be an aid in identifying patients with non–small cell lung cancer and gastrointestinal cancers who are eligible for pembrolizumab (Keytruda) monotherapy.

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

Hope S. Rugo, MD, discusses the importance of individualizing doses of nab-paclitaxel in triple-negative breast cancer.

Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.

Lisa Carey, MD, discusses the challenges with de-escalation in patients with TNBC and steps toward overcoming these obstacles.

Arti Hurria, MD, discusses the unique challenges with treating elderly patients with breast cancer and the exciting opportunities she envisions for advancing care in this setting.

Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

Christophe Massard, MD, PhD, discusses the latest developments with durvalumab (Imfinzi) in urothelial carcinoma.

Richard M. Stone, MD, discusses the impact that midostaurin could have for patients with AML, as well as ongoing research with the agent.

Leah Ralph discusses the ACCC’s position on the Afforadable Care Act repeal bill, the Medicare Payment Advisory Commission’s Part B cost control proposals, and the possibility for comprehensive reform on the 340B Drug Discount Program.

Dana Chase, MD, discusses obstacles to progress and her hope for the future in advanced gynecologic cancers.

Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.

Matthew B. Yurgelun, MD, discusses a study that determined that nearly 10% of patients with colorectal cancer had germline cancer susceptibility gene mutations and its implications for patients and their families.

Julie R. Brahmer, MD, discusses the 5-year findings of nivolumab in non-small cell lung cancer, their significance, and expected next steps for this research.

Steven H. Lin, MD, PhD discusses the benefits of advanced radiation technologies, including intensity-modulated radiation therapy and proton therapy, specifically for patients with esophageal cancer.

Evan Y. Yu, MD, discusses the current treatment options for patients with metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

James B. Yu, MD, discusses results of a study on moderate hypofractionation in patients with prostate cancer, as well as recent data demonstrating how genomic testing can be helpful in postoperative treatment decision making.

Emma Barber, MD, discusses the impact of neoadjuvant chemotherapy on readmission rates, and how the goal of lowering readmission rates in ovarian cancer may not always align with optimizing long-term outcomes.

Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.

A prophylactic treatment of loperamide plus budesonide reduced the rate of grade 3 diarrhea associated with neratinib.

According to Nancy Gordon, MD, immunotherapy stands to play a critical role in the treatment of patients with osteosarcoma and lung metastases.

In recent years, advancements in the treatment of patients with metastatic melanoma have proceeded in 2 areas: targeted therapies and immunotherapies.

In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.

The FDA has approved the marketing of AeroForm, a new system for soft tissue expansion in 2-stage breast reconstruction following mastectomy, and in the treatment of underdeveloped breasts and soft tissue deformities.